Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11439592 Ocular implant containing a tyrosine kinase inhibitor

Overview Structured Data Issues Contributors Activity

Is a

Current Assignee

Ocular Therapeutix, Inc.

Date Filed

March 24, 2021

Date of Patent

September 13, 2022

Patent Applicant

Ocular Therapeutix, Inc.

Patent Application Number

17210696

Patent Citations

US Patent 10300014 Nasolacrimal drainage system implants for drug therapy

US Patent 10420724 Shape changing drug delivery devices and methods

US Patent 10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer

US Patent 10617563 Coated implants

US Patent 10688092 Compositions and methods of using nintedanib for improving glaucoma surgery success

US Patent 10786462 Shape changing drug delivery devices and methods

US Patent 10869924 PD-L1 antagonist combination treatments

US Patent 10874605 Extended release biodegradable ocular implants

US Patent 10874606 Nasolacrimal drainage system implants for drug therapy

US Patent 11053224 Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof

•••

Patent Citations Received

US Patent 11534396 Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Primary Examiner

Carlos A. Azpuru

CPC Code

Find more entities like US Patent 11439592 Ocular implant containing a tyrosine kinase inhibitor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool